Hybrid Immuno-RT for Bulky Tumors: Standard Fractionation with Partial Tumor SBRT.

R Luo, Z Su,K Kang,M Yu, X Zhou, Y Wu, Z Yao,W Xiu,X Zhang,Y Yu, L Zhou, F Na, Y Li,Y Xu,Y Liu, B Zou,F Peng, J Wang, R Zhong, Y Gong,M Huang,S Bai,J Xue, D Yan, Y Lu

International journal of radiation oncology, biology, physics（2023）

Cited 0|Views4

No score

Abstract

ERT/αPD-1 showed superior efficacy in controlling bulky tumor in two mouse models. The hybrid immuno-RT (ERT) combing PD-1 inhibitors was safe and effective in patients with bulky tumors. Further clinical trials in combination with bioimaging to identify the optimal SBRT target region for the bulky tumor are warranted.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined